Working Groups (thematic description)

Slides:



Advertisements
Similar presentations
Replacement of Defective Genes A story of familial hypercholesterolemia By, Russell Brown, Amber Ellis, and Stacey Leonard.
Advertisements

The Diagnostic Laboratory ……the ideal system……. Molecular Genetics Diagnostic Laboratory Exciting area of medical pathology Need to continually up-date.
Regulatory Framework Leigh Shaw, Director.
Retreat Topics iPSC Opportunities in NIAMS Diseases Science Management Forum: Leveraging and Strategic Funding Collaborations Atopic Dermatitis Advancing.
Combating major diseases Gender aspects in research Gender aspects in research have a particular relevance to this theme as risk factors, biological mechanisms,
European Cooperation in the field of Scientific and Technical Research COST is supported by the EU RTD Framework Programme ESF provides the COST Office.
Validity with Pragmatism Specific Issues in experimental design and implementation II-A.
Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.
Cardiovascular Disease: Predicting Risk and Monitoring Outcomes Monica R. Shah, MD, FACC NHLBI AIDS Coordinator Conference on Retroviruses and Opportunistic.
Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing
C-REACTIVE PROTEIN, FIBRINOGEN, AND CARDIOVASCULAR DISEASE PREDICTION By Patrick Whitledge PA-S2 South University Physician Assistant Program.
The South African Malaria Initiative A Case Study E Jane Morris Bridging the Gap in Global Health Innovation - from Needs to.
Bioinformatics Jan Taylor. A bit about me Biochemistry and Molecular Biology Computer Science, Computational Biology Multivariate statistics Machine learning.
Role of PXR Signaling in Mediating the Cardioprotective Effects of  -3 Fatty Acids Saraswathi Viswanathan, Ph.D. Assistant Professor Department of Internal.
THE LIPID PANEL What are we missing? Robert St. Amant, MD, FAAFP Diplomate, American Board of Clinical Lipidology Baton Rouge General Medical Director,
Global impact of ischemic heart disease World Heart Federation, 2011.
Unit 5 – Public Health Chronic Diseases
Epigenome 1. 2 Background: GWAS Genome-Wide Association Studies 3.
Web of Causation; Exposure and Disease Outcomes Thomas Songer, PhD Basic Epidemiology South Asian Cardiovascular Research Methodology Workshop.
The Human Genome Project: prospects for cardiology Claude L’Enfant MD Director, National Heart, Lung, and Blood Institute National Institutes of Health,
European Cooperation in the field of Scientific and Technical Research COST is supported by the EU RTD Framework Programme ESF provides the COST Office.
NT CVD : Development and Validation of new Diagnostic, Preventive and Therapeutic Tools for the Prevention of Cardiovascular Disease in Chronic Kidney.
The role of HDL in atherosclerosis Prof. M. John Chapman (Paris, France) in discussion with Dr. Kees Hovingh (Amsterdam, The Netherlands)
OMICS Group Contact us at: OMICS Group International through its Open Access Initiative is committed to make genuine and.
CAST Project funded by the European Commission, Directorate-General Energy & Transport, under the 6th RTD Framework Programme.
OMICS Journals are Welcoming Submissions OMICS International welcomes submissions that are original and technically so as to serve both the developing.
COST is supported by the EU RTD Framework Programme ESF provides the COST Office through an EC contract European network on applications of Atomic Force.
Bringing Genomics Home Your DNA: A Blueprint for Better Health Dr. Brad Popovich Chief Scientific Officer Genome British Columbia March 24, 2015 / Vancouver,
Dr Godfrey Grech University of Malta
Familial coronary artery disease Paul Brennan Clinical Director Northern Genetics Service Newcastle Hospitals NHS Foundation Trust North East and North.
Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.
Improving health properties of food by sharing our knowledge on the digestive process FA1005 Start date: 05/04/2011 End date: 04/04/2015 Year: Starting.
HANDBOOK OF DYSLIPIDEMIA AND ATHEROSCLEROSIS Part One Professor Jean-Charles Fruchart Department of Atherosclerosis (Inserm UR545) Pasteur Institute of.
Jerrold J. Heindel PhD Acting Chief Cellular Organ and Systems Pathobiology Branch National Institute of Environmental Health Sciences National Institutes.
The presence of cardiovascular disease is an important predictor of mortality in patients with end-stage renal disease, as it accounts for almost 50 percent.
FACULTY OF APPLIED MEDICAL SCIENCES LABORATORY MEDICINE DEPARTMENT Genetic Risk factors in Gestational diabetes Mr :Shadi Tarazi.
Pharmacology Science that studies interactions of drugs with organism on different levels (subcellular, cellular, organ, systemic) Studies: - relationship.
The cholesterol-ceramide connection as a possible link between
Lipoproteins and Atheroscloresis
Lipoproteins and Atheroscloresis
OMICS Journals are welcoming Submissions
Cardiovascular Disease
The role of unknown risk factors in coronary heart disease
Szilard Voros, MD, FACC, FSCCT, FAHA Chief Executive Officer | Founder
“The String Theory Universe”: A EU project in Physics with a
Cardiovascular Research Institute Washington Hospital Center
Triglycerides (mmol/L)
The paradigm by which an increase in the inflammatory burden in RA is associated with the lowering of lipid levels has also been noted in other chronic.
Brain Extracellular Matrix in Health and Disease
Action: BM0806 Recent Advances in Histamine Receptor H4R Research
Action:Urine and Kidney Proteomics (EuroKUP, BM0702)
OMICS Journals are welcoming Submissions
Gene Editing Tools and Methods
HDL and Atherosclerosis
Dept of Biomedical Informatics University of Pittsburgh
Case Study #2 Session 1, Day 3, Liu
Biopharmaceutics Dr Mohammad Issa Saleh.
Genetics and epigenetics of NAFLD and NASH
Alcohol and toxicity Journal of Hepatology
VWF sequence variants: innocent until proven guilty
HDL and Atherosclerosis
Psychiatric Disorders: Diagnosis to Therapy
Florian T. Merkle, Kevin Eggan  Cell Stem Cell 
INTRODUCTION Nutrigenomics Dr. Muhamad Firdaus
Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate
COST and COST Actions Participation of Georgian researchers
Psychiatric Disorders: Diagnosis to Therapy
Introduction to Pharmacogenetics
Potential Mechanisms of Adverse Outcomes Associated with Torcetrapib
M-H Pinard-van der Laan
Presentation transcript:

Working Groups (thematic description) Action: BM0904 (HDLnet) “HDL- From biological understanding to clinical exploitation” Years: 2010-2014 Participating countries: AT, DK, FI, FR, DE, GR, IT, NL, RS, ES, CH, UK Chair of the Action: Dimitris Kardassis, GR, kardasis@imbb.forth.gr Rapporteur: Prof. Marieta COSTACHE Science Officer: Dr Magdalena RADWANSKA Action Website: https://sites.google.com/site/costbm0904/ Scientific background High-density lipoprotein (HDL) is an attractive target for preventing and curing coronary artery disease (CAD) in view of the inverse association between plasma HDL cholesterol and CAD risk as well as the multiple beneficial, anti-atherogenic properties of HDL. As yet, no effective HDL-tailored therapy of CAD is available. This may be due to the fact that HDLs differ in composition and functionality which necessitates the search for the proper biomarkers to assess and monitor HDL-related CAD risk. Working Groups (thematic description) WG1: HDL Structure Reach agreement on best laboratory practice for the analysis and isolation of HDL particles Identify and quantify proteins and lipids belonging to the different HDL subclasses Describe how HDL composition is altered in humans or animal models with specific mutations in HDL metabolism WG2: HDL function Molecular mechanisms underlying normal HDL functionality and HDL dysfunction in common metabolic stress situations such as dyslipidemia, inflammation, diabetes and acute coronary syndromes WG3: HDL Genetics and regulation Identification of new genes, mutations and polymorphisms affecting HDL levels, structure and function via GWAS in the general population and in patient cohorts; deep re-sequencing of individuals with extreme HDL phenotypes Identification of novel regulatory pathways that affect HDL metabolism WG4: HDL physiology Study HDL physiology in vitro and in vivo and the mechanisms underlying reverse cholesterol transport Elucidate the physiological and pathogenic relevance of novel genes and mutations in known HDL genes on HDL biogenesis, remodelling and structure-function WG5: Epidemiological and clinical validation of biomarkers and therapies Explore and validate the diagnostic efficacy of novel lipid or protein biomarker towards assessment and monitoring of cardiovascular risk in populations and patient cohorts. Assess the impact of natural mutations, polymorphisms or new genes on the variation of HDL-related biomarkers and CAD risk Objectives defined in the MoU The scientific objectives of COST BM0904 (HDLnet) are: a) to increase our understanding of HDL structure, function, physiology and genetics b) to understand HDL dysfunction in pathological conditions such as dyslipidemia, diabetes and acute coronary syndromes; and c) to identify and validate novel HDL-based biomarkers in clinical case-control studies as well population-based cohort studies towards their ability to improve cardiovascular risk prediction and in clinical intervention studies towards their ability to reflect the response to anti-atherogenic therapy. . Scientific deliverables obtained due to networking Lipid and protein composition of different HDL subpopulations and their functions in relation to atheroprotection Role of HDL receptors and transporters in the transcytosis of HDL through the endothelial layer New genetic loci and new variants in known HDL genes that are associated with lipid levels in the population Mechanisms of HDL-mediated cholesterol efflux Regulation of HDL levels by cellular pathways and by drugs Capacity building due to networking Formation of a strong network of European scientists in order to foster collaboration and multidisciplinarity in HDL research Sharing of resources (samples and data of population cohorts, animal models of disturbed HDL metabolism) Dissemination of results (meetings, workshops, publications) Technology transfer (STSMs, training schools) Active involvement of Early Stage Researchers and female scientists Formation of precursor networks for EU fp7 grants COST Visibility Scientific Meetings International Workshops on HDL Publications in scientific journals, Articles in Newsletters, Web site